Vandana Zaman

Dr. Vandana Zaman


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ramsha ShamsRamsha Shams
Ramsha Shams
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
VZVandana Zaman
Vandana Zaman
DMDenise Matzelle
Denise Matzelle
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
Spinal cord injury (SCI) affects approximately 300,000 people in the United States. Most individuals who sustain severe SCI also develop subsequent osteoporosis. However, beyond immobilization-related lack of long bone loading, multiple mechanisms of SCI-related bone density loss are incompletely understood. Recent findings suggest neuronal impairment and disability may lead to an upregulation of receptor activator of nuclear factor-κB ligand (RANKL), which promotes bone resorption. Disruption of Wnt signaling and dysregulation of RANKL may also contribute to the pathogenesis of SCI-related osteoporosis. Estrogenic effects may protect bones from resorption by decreasing the upregulation of RANKL. This review will discuss the current proposed physiological and cellular mechanisms explaining osteoporosis associated with SCI. In addition, we will discuss emerging pharmacological and physiological treatment strategies, including the promising effects of estrogen on cellular protection.

14 October 2008 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
VZVandana Zaman
Vandana Zaman
HBHeather A. Boger
Heather A. Boger
AGAnn‐Charlotte Granholm
Ann‐Charlotte Granholm
BRBaerbel Rohrer
Baerbel Rohrer
AMAlfred Moore
Alfred Moore
LMLawrence D. Middaugh
Lawrence D. Middaugh

30 September 2004 in Experimental Neurology
Verified
Journal Article
Closed access
VZVandana Zaman
Vandana Zaman
MNMatthew E. Nelson
Matthew E. Nelson
GGGreg A. Gerhardt
Greg A. Gerhardt
BRBaerbel Rohrer
Baerbel Rohrer

Verified
Journal Article
Open access
PDF file
VZVandana Zaman
Vandana Zaman
KDKelsey P. Drasites
Kelsey P. Drasites
AMAli Myatich
Ali Myatich
Ramsha ShamsRamsha Shams
Ramsha Shams
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
In the central nervous system (CNS), calcium homeostasis is a critical determinant of neuronal survival. Calpain, a calcium-dependent neutral protease, is widely expressed in the brain, including substantia nigra (SN) dopaminergic (DA) neurons. Though calpain is implicated in human Parkinson’s disease (PD) and corresponding animal models, the roles of specific ubiquitous calpain isoforms in PD, calpain-1 and calpain-2, remain poorly understood. In this study, we found that both isoforms are activated in a nigrostriatal pathway with increased phosphorylated synuclein following the administration of rotenone in Lewis rats, but calpain isoforms played different roles in neuronal survival. Although increased expression of calpain-1 and calpain-2 were detected in the SN of rotenone-administered rats, calpain-1 expression was not altered significantly after treatment with calpain inhibitor (calpeptin); this correlated with neuronal survival. By contrast, increased calpain-2 expression in the SN of rotenone rats correlated with neuronal death, and calpeptin treatment significantly attenuated calpain-2 and neuronal death. Calpain inhibition by calpeptin prevented glial (astroglia/microglia) activation in rotenone-treated rats in vivo, promoted M2-type microglia, and protected neurons. These data suggest that enhanced expression of calpain-1 and calpain-2 in PD models differentially affects glial activation and neuronal survival; thus, the attenuation of calpain-2 may be important in reducing SN neuronal loss in PD.

2 December 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
Ramsha ShamsRamsha Shams
Ramsha Shams
VZVandana Zaman
Vandana Zaman
DMDenise Matzelle
Denise Matzelle
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
A spinal cord injury (SCI) may lead to loss of strength, sensation, locomotion and other body functions distal to the lesion site. Individuals with SCI also develop secondary conditions due to the lack of skeletal muscle activity. As SCI case numbers increase, recent studies have attempted to determine the best options to salvage affected musculature before it is lost. These approaches include pharmacotherapeutic options, immunosuppressants, physical activity or a combination thereof. Associated biomarkers are increasingly used to determine if these treatments aid in the protection and reconstruction of affected musculature.